NCT04037657View on ClinicalTrials.gov

Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects.

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 22, 2015

Primary Completion Date

June 9, 2015

Study Completion Date

November 13, 2015

Conditions
AnesthesiaSedation
Interventions
DRUG

HSK3486

HSK3486 was administered as a single dose over a 1 minute infusion period. There were five cohorts of six subjects per cohort (5 HSK3486:1 propofol).

DRUG

Propofol

Propofol, at a dose of 2.5 mg/kg, was administered as a 1 minute infusion at a constant rate via infusion pump.

All Listed Sponsors
lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04037657 - Evaluating the Safety, Pharmacodynamics and Pharmacokinetics of HSK3486 in Healthy Female Subjects. | Biotech Hunter | Biotech Hunter